

FORM PTO-1390 (REV.11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER RICE-006	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NUMBER (DO/EO/US) Unassigned	
INTERNATIONAL APPLICATION NO. PCT/AU00/00982		INTERNATIONAL FILING DATE 08/17/2000		PRIORITY DATE CLAIMED 08/19/1999	
TITLE OF INVENTION DRUG FOR TREATING FRACTURES				EXPRESS MAIL NUMBER EL 027072 04345	
APPLICANT(S) FOR DO/EO/US LITTLE, DAVID G.					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input checked="" type="checkbox"/> is transmitted hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office(RO/US) 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input checked="" type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).					
Items 11 to 20 below concern document(s) or information included:					
11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information: International Preliminary Examination Report with Amended Pages and Postcard					

Unassigned

10/049556

INTERNATIONAL APPLICATION NO.

PCT/AU00/00982

ATTORNEY'S DOCKET NUMBER

RICE-006

21. ☒ The following fees are submitted:

Basic National Fee (37 CFR 1.492(a) (1)-(5)):

Neither international preliminary examination fee (37 CFR 1.482)

nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO.....\$1040.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO.....	\$890.00
---	----------

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....	\$740.00
--	----------

International preliminary examination fee (37 CFR 1.482) paid to USPTO
but all claims did not satisfy provisions of PCT Article 33(1)-(4).....\$710.00

International preliminary examination fee (37 CFR 1.482) paid to USPTO
and all claims satisfied provisions of PCT Article 33(1)-(4).....\$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$1040.00

5

CLAIMS

NUMBER FILED

NUMBER EXTRA

RATE

\$

Total Claims	$43 - 20 =$	23	$\times \$18.00$	\$414.00
--------------	-------------	----	------------------	----------

Independent Claims	$11 - 3 =$	8	$\times \$84.00$	\$672.00
--------------------	------------	---	------------------	----------

MULTIPLE DEPENDENT CLAIMS(S) (if applicable)	+ \$280.00	\$
--	------------	----

TOTAL OF ABOVE CALCULATIONS =

\$2,126.00

<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.	\$1,063.00
---	-------------------

SUBTOTAL =

§

Processing fee of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(f)). ☐ 20 ☐ 30

TOTAL NATIONAL FEE =

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property

TOTAL FEES ENCLOSED = \$1,063.00

\$1.063.00

Amount to be

2

charged:	\$1,063.00
----------	------------

- a. ☐ A check in the amount of \$_____ to cover the fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 50-0815 in the amount of \$1,063.00 to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Depositation Account No. 50-0815. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTG-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revise (37 CFR 1.133(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

SIGNATURE

Alan W. Cannon

NAME _____

34,977

REGISTRATION NO.

CERTIFICATE OF MAILING

EL 824 072 043 US

PRELIMINARY AMENDMENT

Address to:
Box PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

Attorney Docket Confirmation No.	RICE-006 Not Yet Assigned
First Named Inventor	Little
Filing Date	Herewith
Intl. Application Number	PCT/AU00/00982
Intl. Filing Date	17 August 2000
Priority Date Claimed	19 August 1999
Group Art Unit	Unassigned
Examiner Name	Unassigned
Title	Drug For Treating Fractures

Sir:

Prior to examination of the application on the merits, please enter the following amendments:

AMENDMENT**IN THE CLAIMS**

Please cancel claims 1-28 and enter the following new claims:

29. (New) A drug selected from the group consisting of at least one bisphosphonate when used for promoting new bone formation at a fracture site.

30. (New) A drug selected from the group consisting of at least one bisphosphonate when used for treating a fractured bone.

31. (New) The drug of claim 29 wherein the bisphosphonate is Zoledronate.

32. (New) The drug of claim 30 wherein the bisphosphonate is Zoledronate.

33. (New) The drug of claim 29 wherein the drug is a combination of two or more bisphosphonates.

34. (New) The drug of claim 30 wherein the drug is a combination of two or more bisphosphonates.

35. (New) The drug Zoledronate when used for promoting new bone formation.

36. (New) The drug of claim 35 when used for promoting new bone formation between a bone and a prosthesis, bone fixation device or any other bone or dental implant.

37. (New) The drug of claim 29 when administered to an individual as a single dose.

38. (New) The drug of claim 30 when administered to an individual as a single dose.

39. (New) The drug of claim 29 when administered to an individual perioperatively.

40. (New) The drug of claim 30 when administered to an individual perioperatively.

41. (New) Use of a drug selected from the group consisting of at least one bisphosphonate for the manufacture of a medicament for promoting new bone formation at a fracture site.

42. (New) Use of a drug selected from the group consisting of at least one bisphosphonate for the manufacture of a medicament for treating a fractured bone.

43. (New) Use of the drug of claim 41 wherein the drug is Zoledronate.

44. (New) Use of the drug of claim 42 wherein the drug is Zoledronate.

45. (New) Use of the drug of claim 41 wherein the drug is a combination of two or more bisphosphonates.

46. (New) Use of the drug of claim 42 wherein the drug is a combination of two or more bisphosphonates.

47. (New) Use of the drug Zoledronate for the manufacture of a medicament for promoting new bone formation.

48. (New) A method for treating a fractured bone, the method including administering to a subject with a fractured bone a therapeutically effective amount of a drug selected from the group consisting of at least one bisphosphonate.

49. (New) The method of claim 48 wherein the drug is administered to the subject as a single dose.

50. (New) The method of claim 49 wherein the single dose of drug is administered at an early stage of treatment of the fractured bone.

51. (New) The method of claim 48 wherein the mode of administration is as a perioperative intravenous infusion.

52. (New) The method of claim 48 wherein the mode of administration is oral.

53. (New) The method of claim 48 wherein the mode of administration is transdermal.

54. (New) A method of treating a fractured bone, the method including the steps of:

- (a) administering to a subject with a fractured bone a therapeutically effective amount of a drug selected from the group consisting of at least one bisphosphonate; and
- (b) providing a vibratory stimulus to the fractured bone.

55. (New) The method of claim 54 wherein the vibratory stimulus is provided by ultrasound stimulation or vibration stimulation.

56. (New) The method of claim 54 wherein the vibratory stimulus includes periodically providing a vibratory stimulus at the resonant frequency of the bone.

57. (New) The method of claim 55 wherein the vibratory stimulus includes periodically providing a vibratory stimulus at the resonant frequency of the bone.

58. (New) The method of claim 56 wherein the resonant frequency is calculated as a function of the bone's vibratory response to the vibratory stimulus.

59. (New) The method of claim 54 wherein the vibratory stimulus is provided at a late stage in the treatment of the fractured bone.

60. (New) The method claim 54 wherein the step of providing a vibratory stimulus is concurrent with the step of administering a therapeutically effective amount of the drug.

61. (New) The method of claim 60 wherein the vibratory stimulus is provided and the therapeutically effective amount of the drug is administered at an early stage in the treatment of a fractured bone.

62. (New) A drug selected from the group consisting of at least one bisphosphonate when used for promoting new bone formation at a fracture site in an individual suffering from delayed union of a fracture.

63. (New) A method for promoting new bone formation at a fracture site in a subject suffering from delayed union of a fracture, the method including administering to the subject a therapeutically effective amount of a drug selected from the group consisting of at least one bisphosphonate.

64. (New) The method of claim 63 wherein the at least one bisphosphonate is administered parenterally as a single dose at or near the time of surgery.

65. (New) The method of claim 64 wherein a further parenteral dose of the at least one bisphosphonate is administered about four to six weeks after the initial dose.

66. (New) The method of claim 64 wherein further oral doses of the at least one bisphosphonate are administered in a daily or second daily regimen commencing about four to six weeks after the initial dose for a period of about two months or until sufficient new bone has been formed.

67. (New) A method of promoting new bone formation in a subject, the method including the steps of surgically performing the procedure of distraction osteogenesis and administering to the subject a drug selected from the group consisting of at least one bisphosphonate.

68. (New) The method of claim 67 wherein the at least one bisphosphonate is administered parenterally as a single dose at or near the time of surgery.

69. (New) The method of claim 68 wherein a further parenteral dose of the at least one bisphosphonate is administered either at the end of the distraction period or up to three months after the initial dose.

70. (New) The method of claim 68 wherein further oral doses of the at least one bisphosphonate are administered in a daily, second daily or weekly regimen.

71. (New) The method of claim 70 wherein the regimen commences about one to three months after the initial parenteral dose for a period of about two months.

2025-06-20 09:07:02

REMARKS

Formal Matters

Claims 29-71 are pending after entry of the amendments set forth herein.

Applicants respectfully request reconsideration of the application in view of the amendments and remarks made herein.

No new matter has been added.

Conclusion

The Commissioner is hereby authorized to charge any underpayment of fees associated with this communication, including any necessary fees for extensions of time, or credit any overpayment to Deposit Account No. 50-0815.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date:

February 12, 2002

By:



Alan W. Cannon
Registration No. 34,977

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

10/049556

Drug for Treating FracturesField of the Invention

The present invention relates to new indications for a certain class of drugs. More specifically, the present invention relates to the use of bisphosphonates for the promotion of bone growth and in the treatment of bone fractures. Of the bisphosphonates, Zoledronate and Pamidronate have been found to be particularly effective when used for such a purpose.

Background Art

Bisphosphonates are characterised by a P-C-P bond, which has a strong affinity for bone mineral. They are analogues of pyrophosphate, containing a carbon instead of an oxygen atom. This makes them totally resistant to enzymatic breakdown in vivo.

Bisphosphonates differ in their actions and potency depending on the configuration of a side chain. Bisphosphonates inhibit bone resorption through a direct effect on osteoclast function, and also inhibit osteoblastic recruitment of osteoclasts. Due to these factors, calcium is retained in the skeleton and there is a subsequent increase in parathyroid hormone (PTH) and 1,25-(OH)₂ vitamin D, leading to increased intestinal calcium absorption. In growing rats this has resulted in an increase in bone mass (Licata, "Bisphosphonate Therapy" *Am J Med Sci* 1997 Jan; 313(1):17-22). In very high doses, bisphosphonates may actually inhibit bone formation and osteoblast function. In fact one of the previously well-documented indications for bisphosphonates is in the prevention of heterotopic ossification after spinal cord injury or hip arthroplasty. (Stover et al "Disodium etidronate in the prevention of postoperative recurrence of heterotopic ossification in spinal-cord injury patients" *J Bone Joint Surg Am* 1976;58(5):683-8 and Finerman and Stover "Heterotopic ossification following hip replacement or spinal cord injury. Two clinical studies with EHDP." *Metab Bone Dis Relat Res* 1981;3:337-42 and Banovac and Gonzalez "Evaluation and management of heterotopic ossification in patients with spinal cord injury". *Spinal Cord* 1997;35:158-62.)

The bisphosphonate etidronate, was first trialed for the treatment of primary osteoporosis many years ago. Results showed some success in increasing bone density and possibly controlling fracture rates (Licata, *supra*).

Since then, the use of bisphosphonates in the treatment and

prevention of osteoporosis has become well known. They are particularly valuable in the management of postmenopausal osteoporosis but indications for the use of these drugs in the treatment of other disorders affecting bones has also become well known.

Because bisphosphonates are capable of inhibiting bone resorption they are used as effective therapeutic agents in several conditions characterised by increased bone turnover, including Paget's disease, hypercalcaemia of malignancy and metastatic bone disease (Lombardi, "Clinical trials with bisphosphonates" *Ann Ital Med Int* 1992 Jul-Sep; 7(3 Suppl):158S-165S). They have also been indicated in the treatment of multiple myeloma, breast cancer metastases and osteogenesis imperfecta.

Bone fractures are often par for the course in many of these disorders. Even where fractures are avoided, however, their risk of occurrence is dramatically increased by the presence of such disorders. Consequently, much of the ongoing research into the use of bisphosphonates in treating these disorders has centred around the safety of continuing such treatment following a revealed fracture. Many of these studies have found that bisphosphonates have no adverse effects on the restoration of the mechanical integrity of a long bone after fracture or on fracture healing (see, for example, Goodship et al "Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone" *Ann Oncol* 1994; 5 Suppl 7:S53-5; see also Li et al "Effect of Bisphosphonate (Incadronate) on Fracture Healing of Long Bones in Rats" *J Bone Miner Res* 1999 June; 14(6):969-79).

Although the use of bisphosphonates in the above mentioned and other disorders is well documented, "their mode of action is still being unravelled. As a result, their full therapeutic potential is gradually being realised" (see abstract, Russell et al, "Bisphosphonates: from the laboratory to the clinic and back again" *Bone* 1999 Jul; 25(1):97-106).

The present invention provides a considerable number of novel and important indications for the administration of bisphosphonates.

Description of the Invention

In a first aspect, the present invention consists in a drug selected from a group consisting of at least one bisphosphonate when used for promoting bone growth.

Preferably, bone growth is promoted at a fracture site. Furthermore, it is envisaged that bone growth is promoted between a bone and a prosthesis.

bone fixation device or any other bone or dental implant.

In a second aspect, the present invention consists in a drug selected from a group consisting of at least one bisphosphonate when used for treating a fracture.

5 In a preferred embodiment, the drug of either the first or the second aspect is the bisphosphonate Zoledronate.

In a further preferred embodiment, the drug of either the first or the second aspect is the bisphosphonate Pamidronate.

10 In another embodiment, the drug may be another drug from the group consisting of bisphosphonates or a combination of two or more bisphosphonates.

In a third aspect, the present invention consists in the use of a drug selected from a group consisting of at least one bisphosphonate for the manufacture of a medicament for promoting bone growth.

15 In one embodiment of the third aspect, the drug promotes bone growth at a fracture site.

In a further embodiment, the drug promotes bone growth between a bone and a prosthesis.

20 In a fourth aspect, the present invention consists in the use of a drug selected from a group consisting of at least one bisphosphonate for the manufacture of a medicament for treating a fractured bone.

In a fifth aspect, the present invention consists in a method for treating a fractured bone, the method including administering to a subject with a fractured bone a therapeutically effective amount of a drug selected from the group consisting of at least one bisphosphonate.

25 Preferably, the drug is administered to the subject as a single dose. It is further preferred that the single dose of drug is administered at an early stage of treatment of the fractured bone.

30 In a sixth aspect, the present invention consists in a method for treating a fractured bone, the method including the steps of:

(a) administering to a subject with a fractured bone a therapeutically effective amount of a drug selected from a group consisting of at least one bisphosphonate; and

(b) providing a vibratory stimulus to the fractured bone.

35 Preferred embodiments disclose that the use of a drug from the class of bisphosphonates in promoting bone growth or treating a fracture may be

applicable to all clinical alternatives for managing a fractured bone: many fractures are most appropriately managed by simply applying a plaster cast to the site at which the fracture has occurred and allowing the bone to heal whilst splinted in that way; some fractures simply require the patient to rest: some fractures may require the application of a range of surgical interventions; and other fractures are appropriately managed with a combination of the latter two alternatives. Furthermore, as an alternative or an addition, as disclosed above, the step of providing of a vibratory stimulus to the fractured bone may also be desirable in certain circumstances. Which ever of these, or other, clinical alternatives is/are chosen for managing a fractured bone, the present invention discloses the administration of at least one drug from the class of bisphosphonates to the patient.

There may be several advantages to using at least one drug from the class of bisphosphonates in the treatment of bone fractures. Many of these are disclosed in considerable detail below. Nevertheless, for reasons which will now become clear, it is worthwhile noting some of the more general advantages from the outset. They include, but are not limited to, the following: bisphosphonates can stimulate osteoblast proliferation and increase callus formation; they are also potent inhibitors of osteoclastic bone resorption; they aid in the prevention of osteoporosis, and therefore decrease disuse osteoporosis associated with the injury; and they may also significantly decrease the length of time which is taken for a fracture to heal.

According to this invention, the circumstances in which bisphosphonates are applicable to the management of fractures are far reaching. Indeed, preferred embodiments disclose that the situations in which bisphosphonates may be indicated in fracture care include at least:

- (i) Increasing new bone formation in distraction osteogenesis:
 - (a) Bone lengthening
 - (b) Bone transport
- (ii) Increasing new bone formation in fractures treated by open reduction
- (iii) Increasing new bone formation in fractures treated by intramedullary fixation
- (iv) Increasing new bone formation in fractures treated by external fixation
- (v) Delayed union

- (vi) Improving the ability of bone to support internal fixation devices in osteoporotic individuals or in locally osteoporotic bone segments
- (vii) Treating fractures in which there are potential impediments to uncomplicated healing, for example:
 - (a) Fractures in the elderly including: neck of femur; supracondylar femur; tibia; ankle; humerus; and the distal radius (note that this list merely provides examples, and the use of bisphosphonates according to this invention is not by any means limited to treating these fractures only, or any other fractures, for that matter, in people of all ages)
 - (b) Pubic rami fatigue fracture
 - (c) Pathological fracture
 - (d) Scaphoid fracture
 - (e) Open fracture
 - (f) Fracture with periosteal disruption
- (viii) Treating fractures that require prolonged immobilisation when treated non-operatively, for example: femoral fractures, tibial fractures; and fractures of the foot and ankle.

Further preferred embodiments also disclose a number of additional indications for using bisphosphonates in orthopaedic procedures. These include administering bisphosphonates to increase ingrowth of bone into joint replacement prostheses; and coating joint prosthesis with bisphosphonates to enhance the latter mentioned ingrowth at a more local level. Such therapy should also reduce the effects of periprosthetic stress shielding. Prosthetic implants may be so coated as an alternative, or in addition to coating with hydroxyapatite or some other osteoinductive coating.

One preferred embodiment discloses that the drug chosen from the class of bisphosphonates for carrying out this invention is Pamidronate. Another preferred embodiment discloses that the drug chosen from the group is Zoledronate. However, in further preferred embodiments, other bisphosphonates may be used in addition (where no adverse interaction results), or as an alternative, to Pamidronate or Zoledronate. Examples of further bisphosphonates include, but are not limited to, Alendronate, Tiludronate, Risedronate, Ibandronate and Incadronate.

In further preferred embodiments, the drug is administered to a

patient as a single dose. In this embodiment, it is preferred that the administration of the drug occurs early during the course of treating the fractured bone as administration of a bisphosphonate at such an early stage has a positive effect on the stimulation and proliferation of osteoblasts.

In a further embodiment, subsequent additional doses may be administered to the patient. In this embodiment, it is envisaged that a response to the first dose would be assessed before administering additional doses.

In still further preferred embodiments, the mode of administration may be as a perioperative intravenous infusion, orally, transdermally or by some other route. Alternatively a course of an oral bisphosphonate may be prescribed. All preferred and alternative embodiments of the invention envisage current and future available modes of administration for the drug. Such modes of administration must, of course be plausible, convenient and provide the patient with a therapeutically effective dose for treating and/or promoting healing of the fractured bone.

The present invention also discloses that in some embodiments, it is preferable to additionally apply a vibratory stimulus to the fractured bone. The vibratory stimulus may be provided by ultrasound stimulation and vibration stimulation, or any other mechanism and/or device capable of providing vibratory stimulation. In some embodiments, the vibratory stimulus may be applied at any frequency which is considered to be effective in the treatment of a fractured bone. In preferred embodiments, however, the step of providing a vibratory stimulus includes periodically providing a vibratory stimulus at the resonant frequency of the bone, said resonant frequency being calculated as a function of the bone's vibratory response to

the vibratory stimulus. In order to have this achieved, this step may be broken down into the following components:

(a) providing a vibratory stimulus to the fractured bone;

(b) detecting the vibratory response of the bone to the vibratory stimulus;

(c) generating a signal representative of the vibratory response;

(d) processing the signal to identify at least one resonant frequency of the bone; and

(e) providing a signal to adjust the vibratory stimulus to the bone such that it is at, or approximate, the bone's at least one resonant frequency.

Whether or not the step of providing a vibratory stimulus to the fractured bone is utilised, preferred embodiments disclose that at least one bisphosphonate should be administered to the patient early in the course of treatment. In this regard, different bones and different types of fracture heal at varying rates. Accordingly, the early phase of the course depends upon such variables.

The administration of a bisphosphonate at such an early stage has a positive effect on the stimulation and proliferation of osteoblasts. In cases where the provision of a vibratory stimulus is utilised, it is preferable that such stimulus be provided later in the course of treatment, since mechanical stimulation will assist in the maturation of the healing fracture. In yet another preferred embodiment, however, both the administration of a bisphosphonate and the provision of a vibratory stimulus may occur early in the course of treatment. In alternative embodiments, they may be used at opposite times, they may be alternated, or they may both be delivered in the later stages of treatment as is considered to be most appropriate.

Brief Description of the Drawings

By way of example, preferred embodiments of the invention are described with reference to the accompanying drawings in which:

Fig. 1 shows the generic formula for bisphosphonates.

Fig. 2 is a graph from example 1 illustrating the differences in Bone Mineral Density (BMD) at the regenerate and at locations both proximal and distal the regenerate in the control group with lengthened legs and the control group with non-lengthened legs (there is, of course, no value given for the BMD at the regenerate for the group with non-lengthened legs);

Fig. 3 is a graph from example 1 illustrating the differences in BMD at

the regenerate and at locations both proximal and distal the regenerate in the pamidronate treated group with lengthened legs and the pamidronate treated group with non-lengthened legs (there is, of course, no value given for the BMD at the regenerate for the group with non-lengthened legs);

Fig. 4 is a graph from example 1 illustrating the differences in BMD at the regenerate and at locations both proximal and distal the regenerate in the control group with lengthened legs and the pamidronate treated group with lengthened legs;

Fig. 5 illustrates the histopathological differences between a specimen from the control group and one from the pamidronate treated group of example 1;

Fig. 6 is a graph from example 2 illustrating the differences in peak load for the non-operated and operated pamidronate treated group and for the non-operated and operated control group; and

Fig. 7 is a graph from example 2 illustrating the difference in findings with respect to Young's Modulus (1% strain) for the non-operated and operated pamidronate treated group and for the non-operated and operated control group.

Figures 8A, 8B and 8C are graphs from example 3 illustrating the bone mineral content in the proximal, regenerate and distal segments of an operated tibia at 2, 4 and 6 weeks post operation respectively.

Figure 9 is a graph from example 3 illustrating Bone Mineral Content (BMC) accrual in the regenerate.

Figure 10 is a graph from example 3 illustrating final BMC at six weeks as measured by QCT.

Figures 11A, 11B and 11C are graphs from example 3 illustrating BMD in the proximal, regenerate and distal segments of an operated tibia at 2, 4 and 6 weeks post operation respectively.

Figure 12 is a graph from example 3 illustrating final BMD at six weeks as measured by QCT.

Figure 13 is a graph from example 3 illustrating final cross-sectional area at six weeks as measured by QCT.

Figure 14 depicts QCT scans from example 3 of regenerate in rabbit operated tibiae that were the median for cross sectional area in each group.

Figure 15 is a graph from example 3 illustrating final moment of inertia at six weeks as measured by QCT.

Figure 16 is a simplified view of a device for the application of a vibratory stimulus to a fractured bone.

Preferred Mode of Carrying Out the Invention

In preferred embodiments, zoledronate or pamidronate and/or another
5 drug from the class of bisphosphonates is used for the manufacture of a medicament for promoting bone growth or treating a fractured bone.

A therapeutically effective dose of the medicament, or zoledronate or pamidronate and/or another bisphosphonate alone, is then appropriately prepared and administered to a patient via an intravenous route.

10 Preferred embodiments further disclose that such administration of the drug is to occur early during the course of treating the fractured bone. The administration of a bisphosphonate at such an early stage has a positive effect on the stimulation and proliferation of osteoblasts. No further administration of the bisphosphonate may be required, but can be
15 administered if desirable after gauging the response of the patient to the first dose.

Furthermore, a course of an oral bisphosphonate may be prescribed to a patient wherein the oral bisphosphonate is taken in the initial three months of fracture healing. In another embodiment, a course of oral bisphosphonates
20 may be given later in the course of fracture healing to augment callus formation in a bone healing slowly.

The present invention also discloses that in some embodiments, it is preferable to additionally apply a vibratory stimulus to the fractured bone as set out in International Application No PCT/AU99/00974 and herein
25 incorporated by reference. The vibratory stimulus may be provided by ultrasound stimulation and vibration stimulation, or any other mechanism and/or device capable of providing vibratory stimulation. In such preferred embodiments, the step of providing a vibratory stimulus includes periodically providing a vibratory stimulus at the resonant frequency of the bone, said resonant frequency being calculated as a function of the bone's
30 vibratory response to the vibratory stimulus.

With reference to Figure 16, the vibratory stimulation device 10 is adapted to determine the specific resonant frequency of a bone 11, and to then subject the bone 11 to stimulation at the specific resonant frequency of
35 the bone 11, and maintain stimulation at that frequency for a period of time. This ensures optimal stimulation and thus optimal promotion of bone mass.

whilst at the same time, avoids the risk of over-stimulation or overloading, and thus, fracture of the bone.

The device 10 includes a vibration stimulator 12 which, when activated, stimulates the bone 11 over a range of frequencies, causing vibration of the bone 11. The stimulator 12 is driven by a signal generator housed in the computer 14. The signal generator, when initially activated, can cause the stimulator 12 to vibrate over a range of frequencies. The signal generator can, for example, sweep through this range of frequencies.

Examples of suitable stimulators 12 include a rotating eccentric mass, an electromagnetic shaker, and a variable frequency pulsed ultrasonic transducer. The stimulator 12 can incorporate a stimulus sensor, such as a force transducer, to monitor the stimulus provided to the bone by the stimulator 12.

The vibrations are detected by a detector 13. The detector 13 can comprise an accelerometer or a plurality of accelerometers. The detector 13 transmits the signals to a computer 14 wherein the signals are converted from analogue to digital form and then processed to determine the frequency domain characteristics of the vibratory response. The computer 14 can incorporate an automatic analysing means that determines the peak acceleration/velocity/displacement of the bone and so determines the resonant frequency of the bone. In another embodiment, the computer can display either numerically and/or graphically the measured characteristics of the vibratory response to allow manual determination of the resonant frequency by a user of the device, or a treating physician. The device 10 can include a manual frequency control 15 for stimulation. Preferably, from the signals received, the computer 14 identifies one of the resonant frequencies of the bone 11 and transmits a signal to the stimulator 12 to stimulate the bone 11 at, or approximate, the one resonant frequency.

The device can incorporate a timer that allows the time of operation of the stimulator 12 to be pre-set prior to activation. Such a time might be set by making an appropriate entry into a software programme running on the computer 14. Preferably, adjustment to the amplitude of the vibratory stimulus can be made by suitable entries into the software running on the computer 14.

Whilst Figure 16 depicts a simple representation of the device whereby the vibration stimulator 12 and the detector 13 are applied to the bone via an

external frame 16, it is envisaged that they would be applied either to the skin of the affected limb, wherein the stimulation of the bone could be imparted transcutaneously, or via a frame, or other like device surrounding the limb, and in particular, a plaster cast.

5 It is further envisaged that this method of treatment be used in the treatment of several bone disorders to promote bone tissue growth and also to maintain bone mass. Examples include the healing of a fracture site wherein the vibration caused to the bone results in micro-movement, bending or torsion at the site of fracture which in turn leads to promotion of bone
10 healing. The stimulation also causes micro-movement, bending or torsion of the intact portions of the bone, which in turn, leads to promotion of bone formation and prevention of osteoporosis in the intact bone. As the stimulation imparted by device 10 is regulated to be at the same, or approximately the same, frequency as the resonant frequency of the bone, the
15 promotion of bone tissue growth is optimised and occurs at a faster rate than if the bone is simply stimulated at a frequency unrelated to the resonant frequency of the bone.

Similarly, it is readily envisaged that the device 10 could be applied
transcutaneously to a bone with a fixation means such as an intramedullary
20 nail holding the bone pieces together. In this manner, the formation of bone between the pieces of bone may be increased by the stimulation of the bone and the fixation means at, or approximate, the bone's resonant frequency.

It can also be envisaged that the device 10 can be transported readily
and therefore used in a patient's home. In this way, the device 10 would be
25 pre-programmed such that all the patient need do to use the device would be to attach the vibration stimulator 12 and the vibration detector 13 to the affected limb, or other body part, and activate the device 10.

In cases where the provision of a vibratory stimulus is utilised, it is
preferable that such stimulus be provided later in the course of treatment.
30 since mechanical stimulation assisting in the maturation of the healing fracture. In yet another preferred embodiment, however, both the administration of a bisphosphonate and the provision of a vibratory stimulus may occur early in the course of treatment. As disclosed above, however,
these two modes of treatment may be used at opposite times. they may be
35 alternated, or they may both be delivered in the later stages of treatment as is considered to be most appropriate.

The foregoing disclosure will now provide a more detailed analysis of the effects which the administration of a drug according to a preferred embodiment of the invention has on the healing process, and therefore, treatment of a fractured bone.

Each of the following examples relates to the administration of a bisphosphonate in distraction osteogenesis. One of the aims of distraction osteogenesis is to lengthen the limb upon which the procedure is performed. The performance of a distraction osteogenesis necessitates fracturing of the bone. Following placement of an external frame on the limb, the bone is cut. During healing, the new bone forms as the frame is slowly distracted.

It is because the bone is fractured during the procedure, that the results of a study involving distraction osteogenesis are appropriate for illustrating the effects which the administration of pamidronate has on bone.

Example 1: Pamidronate in Distraction Osteogenesis (dose 3mg/kg)

Methods:

Experimental design

Twenty eight-week-old male NZW rabbits underwent tibial lengthening. Similar rabbit models have been reported. After premedication with IM Ketamine 15 mg/kg and Xylazine 4mg/kg, anaesthesia was administered with Halothane 2%, and Oxygen 1 l/min. An open mid-tibial drill hole osteotomy was performed on each rabbit and an Orthofix M-100 fixator was applied using four Orthofix 3 mm half pins (Orthofix, Bussolengo, Italy). After a latency of 24 hours the tibia was lengthened 0.375mm every 12 hours for 15 days, producing an 11.25 mm distraction. The fixator was then left in situ for 27 days to allow the regenerate to consolidate. Pamidronate 3.0 mg/kg diluted to 30mg/100ml was administered as a single intraoperative infusion over two hours to 10 of the rabbits; 10 control animals were given saline infusions. Buprenorphine 0.05 mg/kg was administered at the end of surgery and again 12 hours post operatively. The animals were supplied with rabbit pellet and water ad libitum. At 42 days the rabbits were sacrificed with IV Lethobarb 150mg/kg.

Radiographic and Bone Mineral Density Analysis

Both hind limbs were disarticulated through the knee and the soft tissues left intact. The limbs were oriented in standard AP and lateral projections and plain radiographs taken with a Siemens Multix H/UPH configuration using digital luminescent cassettes with a 50 kV and 4 mA

exposure with a tube to film distance of 1.1 meters. The distance between pin sites was measured from each dissected specimen so that each radiograph could be re-scaled appropriately for measurements of regenerate length.

5 Bone mineral density (BMD) measurements were made using a total body dual energy x-ray densitometer (LUNAR DPX, Radiation Corps, Madison, Wisconsin). DXA has been used in this context in previous reports. BMD scans were performed with the tibia oriented in the antero-posterior (AP) and lateral projections, using software specifically designed for
10 measuring small animals (LUNAR DPX, Small Animal Software. 1.0c LUNAR, Radiation Corps, Madison, Wisconsin). The "HiRes <0.5kg Slow" scan mode was used ("Fine" collimation, sample size of 0.6 x 1.2 mm, and sample interval of 1/16 seconds). To calculate CV's of the machine, thirty scans were performed on a rabbit forelimb over the duration of the study period. CV's of the BMD, measured by positioning three boxes on each scan,
15 were 3.6%, 4.5% and 5.7% respectively (from proximal to distal).

Regional BMD measurements were obtained by placing "regions of interest" (ROI's) 9.6 mm high on the scan images. For each lengthened tibia, one ROI was positioned in the regenerate, one proximal to it and one distal to it. In the non-operated tibia, two ROI's were placed so that they matched the distal and proximal ROI of the lengthened tibia (ie the same distance from the bone ends). A total of three measurements were thus generated for each lengthened tibia and two measurements for each non-operated tibia, for each projection. BMD values were expressed as g/cm² and group data reported as
20 mean and standard deviation. Lengthened and non-operated tibia samples were compared using paired t-tests; non-paired tests were used to compare between groups.

Histological Analysis

25 The histological analysis was performed in a blinded fashion by two pathologists who were observers. Five pairs of tibiae from the Pamidronate group and five controls were excised sub-periosteally and fixed in 10% buffered formalin. Each bone was transversely sectioned into proximal, regenerate and distal bone segments prior to decalcification in standard EDTA solution over 48 hours. Each segment was then longitudinally sliced and half embedded in paraffin blocks yielding six blocks per rabbit. Sections
30 for microscopy were cut at 5 microns and stained with haematoxylin and

eosin. Both pathologists examined all the sections and made a consensus assessment of the amount of new bone formation, cortical thickness, extent of remodelling, and bone formation around the pin sites. As cortical thickness would be expected to alter depending on the plane of sectioning, it was not measured precisely. The osteoclast activity in the regenerate was expressed as number per high-powered field (Olympus, BH2, 40x objective). The degree of osteoblastic rimming was also assessed.

Results:

Exclusions

There were 3 postoperative complications necessitating exclusion from DXA analysis: one tibial fracture noted on day 1 near the distal pin sites (pamidronate group); one femoral fracture on day 23 requiring euthanasia (pamidronate group); and one common peroneal nerve palsy (control).

Control Rabbit Model

Reliable bone formation occurred in the distraction gap. All tibiae were clinically and radiographically united at day 42. BMD values from the AP scan for the lengthened and non-operated limbs are shown in figure 2. There was a significant reduction in BMD in both the proximal and distal segments surrounding the lengthening compared with the matched sites in the non-operated limb ($p < 0.02$). Similar significant differences were present on the lateral scans.

Pamidronate Group

The reduction in BMD in the proximal and distal segments was not found in the pamidronate group, with no significant difference in BMD between the bone of the operated and non-operated limbs at six weeks ($p = 0.332$ proximal, $p = 0.256$ distal) (Figure 3). The same effect was seen on the lateral scans.

Figure 4 compares the BMD from AP scans of the operated limbs for rabbits given pamidronate versus controls. The BMD of the proximal and distal bone surrounding the regenerate has increased by a mean of 40% and 39% respectively ($p < 0.01$). The BMD in the regenerate was increased by a mean of 43% over the control rabbit tibiae ($p = 0.017$). Lateral scans also confirmed the above significant differences.

The BMD for the non-operated limbs of control and pamidronate groups was not significantly different. These results are compared in Table 1. There was an increase in the mean regenerate area of 22% in the

pamidronate group ($p < 0.05$).

Histology

Of the ten specimens collected, nine were examined histologically. The rabbit culled on day 23 was not included in the analysis. The tibiae from the pamidronate group took 24-48 hours longer to decalcify than the control specimens. The pamidronate group demonstrated increased regenerate formation with prominent osteoblastic rimming and decreased numbers of osteoclasts (2.4 / HPF v 3.4 / HPF in controls) with less evidence of bone remodelling (Fig 5). There was also increased endosteal bone formation in the bone cortex adjacent to the regenerate, producing an increase in cortical thickness (Fig. 5). There was a marked increase in bone formation around the pin sites in the pamidronate group. There was a degree of variability in these factors within the pamidronate group, as with the variability seen in BMD values.

Discussion:

In this experiment, a single dose of 3 mg/kg of pamidronate was given to the rabbits at the beginning of the lengthening to minimise negative effects on bone remodelling. This strategy abolished the osteoporosis seen in controls and had a markedly positive effect on osteoblast activity and bone mineral accretion in the regenerate. Osteoclast number and activity remained reduced at day 42. As the pamidronate was given at the time of surgery, the marked increase in regenerate formation and mineralisation is most interesting. Either pamidronate from the surrounding bone leached out into the regenerate bone to exert a local effect, or the increase in regenerate was due to an anabolic effect secondary to changes in PTH and 1,25-(OH)₂ vitamin D. Further research is required to evaluate these hypotheses.

It was hypothesised that a pulsatile pre-dosage regimen would be desirable when coincident with surgical intervention. As pamidronate has a strong affinity for bone mineral, it is possible to load the skeleton with a pulsatile dose that will exert a positive effect for three to six months (Glorieux et al, "Cyclic administration of pamidronate in children with severe osteogenesis imperfecta" *N. Engl. J Med* 1998; 339: 947-52). Li et al (*supra*) set out to determine if patients receiving continuing bisphosphonate therapy should have this treatment withdrawn in the event of a fracture. They showed increased callus formation in rat femoral fractures pre-treated with incadronate. Continuation of therapy for sixteen weeks after fracture

increased callus formation even further. but the new bone did not remodel to form a cortical shell as in the pre-treated group. They concluded that the therapy should be ceased to allow remodelling, but that more study was needed.

5 Apart from negative effects on remodelling, continuous dosing with bisphosphonates may not be desirable in distraction osteogenesis because of a detrimental effect on longitudinal growth. In a study using daily subcutaneous alendronate, normal growing mice showed diminution in leg length, as well as decreased ductility after treatment (Raggio et al, 10 "Alendronate reduces fractures without increasing bone strength in a growing mouse model of osteogenesis imperfecta" *Proceedings of Paediatric Orthopaedic Society of North America*, May, 1999). In the experiment, no significant change in leg length was noted, although there was a suggestion of growth inhibition – the non-operated limbs in the control group were longer than those of the pamidronate group by 1.4mm. There were no limb measurements taken at the time of operation, so this difference could not be attributed to growth inhibition with absolute certainty. However, growth inhibition may well have been minimised by the one dose regimen. The study of Li et al (*supra*) did not comment on longitudinal growth, but the comparison radiographs indicate that the continually treated rat femora were shorter than those of the pre-treated and control groups.

15 The histologic findings in this study suggest an increase in bone formation, as well as a decrease in bone resorption following the administration of pamidronate. This was found particularly in the endosteal region of the bone surrounding the lengthening as well as in the regenerate. 25 and was more obvious in the operated leg. Other studies have recently suggested that bisphosphonates influence cells of osteoblastic lineage in a fashion distinct from their inhibitory effects on osteoclasts (Giuliani et al, "Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo" *Bone* 1998, 30 May; 22(5):455-61).

As pamidronate increased the bone forming capacity of the regenerate, it is possible that it's use may increase the risk of premature consolidation. 35 The length of the regenerate was decreased by a mean of 0.8 mm (8%) in the rabbits given pamidronate. While this small amount is not alarming, the

difference did reach statistical significance, such that careful observation for this possibility would be required if pamidronate were used clinically.

One rabbit given pamidronate sustained a femoral fracture in their operated limb on day 23. This may have been a random event. however it is possible that the bone was made brittle by the pamidronate.

The toxicological effects of bisphosphonates in children are yet to have been fully evaluated. The dose of 3 mg/kg for this experiment was chosen because that is the dose commonly given to children with osteogenesis imperfecta (Glorieux et al, *supra*).

The large increase in BMD throughout the lengthened limb that were obtained following a single dose of pamidronate may have a positive therapeutic effect in children undergoing limb lengthening. The fact that pamidronate increased the amount of regenerate that formed provides a promising prospect worth continuing evaluation. Further investigations into the mechanical properties of the bone after pamidronate treatment, refinement of the dosage regimen and examination of possible toxicological effects are required prior to a clinical trial.

Table I

Comparison of Mean Data between Pamidronate and Control Groups Standard Deviation, upper and lower 95% Confidence Limits in Parentheses					
<i>Variable</i>	<i>Pamidronate</i>	<i>Control</i>	<i>Difference</i>	<i>95% CI</i>	<i>p value</i>
Length of lengthened limb (mm)	106.0 (3.4)	107.6 (4.5)	-1.57	(-5.76, 2.63)	0.44
Length of non-operated limb (mm)	97.4 (2.0)	98.8 (2.2)	-1.45	(-3.59, 0.74)	0.18
Weight of lengthened tibia (g)	10.9 (0.6)	8.7 (0.9)	2.2	(1.37, 3.03)	<0.001
Weight of non-operated tibia (g)	9.3 (0.5)	8.1 (0.4)	1.19	(0.71, 1.67)	<0.001
Regenerate length (mm)	9.6 (0.6)	10.4 (0.7)	-0.75	(-1.45, -0.04)	0.04
Regenerate area (cm ²)	0.83 (0.09)	0.68 (0.13)	0.15	(0.03, 0.27)	0.017
AP BMD proximal to regenerate (g/cm ³)	0.51 (0.07)	0.36 (0.09)	0.14	(0.06, 0.23)	0.004
AP BMD in regenerate (g/cm ³)	0.47 (0.11)	0.33 (0.11)	0.14	(0.03, 0.25)	0.017
AP BMD distal to regenerate (g/cm ³)	0.48 (0.10)	0.34 (0.08)	0.14	(0.04, 0.23)	0.007
AP BMD in proximal non-operated limb (g/cm ³)	0.48 (0.05)	0.44 (0.03)	0.04	(0.00, 0.09)	0.053
AP BMD in distal non-operated limb (g/cm ³)	0.44 (0.04)	0.42 (0.02)	0.02	(-0.02, 0.05)	0.31

Summary of Findings:

The effect of a single 3 mg / kg dose of pamidronate (Novartis) on Bone Mineral Density (BMD) was examined in a distraction osteogenesis model in immature rabbits.

Seventeen rabbits (9 control, 8 given pamidronate) were examined by Dual X-ray Absorptiometry (DXA). There was a significant increase in BMD in the pamidronate group over controls. The mean areal BMD (g/cm²) in the bone proximal and distal to the regenerate bone was increased by 40% and 39% respectively compared to controls (p<0.05). The BMD of the regenerate bone was increased by a mean of 43% over controls (p<0.05). There was also a 22% increase in mean area of regenerate formed in the pamidronate group (p<0.05).

Histological analysis of nine rabbits (5 control, 4 pamidronate) revealed an increase in osteoblastic rimming and mineralisation of the regenerate in the pamidronate rabbit tibiae. There was also increased bone formation around the pin sites and an increase in the cortical width of the bone adjacent to the regenerate in the rabbits given pamidronate.

Pamidronate had a markedly positive effect in this limb-lengthening model. Not only did it reduce the disuse osteoporosis normally associated with lengthening using an external fixator, it also increased the amount and density of the regenerate bone. Further study to examine the mechanical properties of the regenerate after administration of pamidronate is required.

Example 2: Pamidronate in Distraction Osteogenesis (dose 1mg/kg)

Methods:

Experimental design

Twenty eight-week-old male NZW rabbits underwent tibial lengthening. After premedication with IM Ketamine 15 mg/kg and Xylazine 4mg/kg, anaesthesia was administered with Halothane 2%, and Oxygen 1 l/min. An open mid-tibial drill hole osteotomy was performed on each rabbit and an Orthofix M-100 fixator was applied using four Orthofix 3 mm half pins (Orthofix, Bussolengo, Italy). After a latency of 24 hours the tibia was lengthened 0.375mm every 12 hours for 15 days, producing an 11.25 mm distraction. The fixator was then left in situ for 27 days to allow the regenerate to consolidate. Pamidronate 1.0 mg/kg diluted to 30mg/100 ml was administered as a single intraoperative infusion over two hours to 10 of the rabbits; 10 control animals were given saline infusions. Buprenorphine

0.05 mg/kg was administered at the end of surgery and again 12 hours post operatively. The animals were supplied with rabbit pellet and water ad libitum. At 42 days the rabbits were sacrificed with IV Lethobarb 150mg/kg.

Radiographic and Bone Mineral Density Analysis

Both hind limbs were disarticulated through the knee and the soft tissues left intact. The limbs were oriented in standard AP and lateral projections and plain radiographs taken with a Siemens Multix H/UPH configuration using digital luminescent cassettes with a 50 kV and 4 mA exposure with a tube to film distance of 1.1 meters. The distance between pin sites was measured from each dissected specimen so that each radiograph could be re-scaled appropriately for measurements of regenerate length.

The disarticulated bones were stripped of all soft tissue and analysed using a Stratec XCT-960A pQCT scanner and analysis software (Stratec Medizintechnik GmbH, Pforzheim, Germany). Two millimetre slices were obtained, 15 slices in the right (lengthened) tibiae and 10 in the non-operated tibiae. Five slices were thus obtained in the regenerate, proximal and distal bone, and corresponding areas to the proximal and distal bone in the non-operated limb. Quantitative CT is the noninvasive method with the strongest predictive power for the mechanical strength of newly formed bone (Harp et al., 1994). The software allowed analysis and generation of data on bone mineral density as mg/cm³, bone mineral content (mg) and cross sectional area (mm²). Data was also generated for mechanical analysis, namely moment of inertia (mm⁴), and maximum y co-ordinate (vertical distance from the neutral bending plane in mm).

Strain was calculated for each specimen by formula 1:

$$\text{Strain} = \frac{12Dy}{L^2}$$

D= deflection

y= vertical distance from centre of mass

L= span length

Stress was calculated at 2 mm intervals along the central section of specimen from formula 2:

$$\text{Stress} = \frac{My}{I}$$

M= moment at x

$$= \frac{\text{load}}{2}x - \frac{\text{load}}{2}(x - L/4)$$

y = vertical distance from centre of mass

I = second moment of inertia

x = distance along bone from left roller

The Young's modulus of elasticity was calculated as the slope of the linear portion of the stress/strain curve for each "slice" or 2 mm interval.

The mean Young's modulus values for the control and treated groups at both the central "slice" and for averaged data over the central 1 cm of regenerate section, were compared using an unpaired two tailed t-test.

The area under the stress strain curves for the central "slice" was calculated for the distracted tibiae in both control and pamidronate groups. These were again compared with an unpaired two-tailed t test.

Results:

Reliable bone formation occurred in the distraction gap. All tibiae were clinically and radiographically united at day 42. There was a significant increase in bone mineral density proximal and distal to the regenerate in the pamidronate group (Table II). There were also significant increases in bone mineral content. There was a 13% increase in bone area, although this was not statistically significant ($p=0.2$).

The lengthened tibiae in the pamidronate group were 32% stronger for peak load ($p=0.004$) (Fig 6). The peak load in the lengthened tibiae in the pamidronate group was the same as that for the non-operated control tibiae. Young's modulus was not significantly different between operated groups, and was reduced to only about 30% of the value of the in tact tibiae (Fig 7).

Discussion:

In this experiment, a single dose of 1.0 mg/kg given to the rabbits at the beginning of the lengthening produced significant improvement in peak load at six weeks measured by four point bending. As in our previous experiment, osteoporosis surrounding the lengthening was reduced. Although not statistically significant, there was an increase in callus area, but not as marked as had occurred in specimens from the group in the previous experiment treated with 3.0 mg/kg of pamidronate.

The increase in peak load is likely to be due to both increased regenerate volume and increased mineral content at six weeks. The fact that modulus of elasticity remained unchanged with pamidronate indicates that

the bone may be no more mature than in controls. Combining bisphosphonate treatment and mechanical stimulation may prove to be beneficial; the hypothesis being that the bisphosphonate will increase early osteoblastic proliferation and increase bone mineral content, while the mechanical stimulation would accelerate callus maturation.

TABLE II

Comparison of Data between Control and Pamidronate Groups						
	Control		Pamidronate		% increase	P value
	Mean	SD	Mean	SD		
TOT BMC Prox	27.98	6.68	34.52	6.27	23%	0.03
TOT BMC Regen	26.13	10.70	30.47	6.67	17%	NS
TOT BMC Dist	28.04	4.65	34.47	4.34	23%	0.004
Total BMD Prox	585.53	69.61	650.73	47.06	11%	0.03
Total BMD Regen	530.06	77.61	575.03	62.12	8%	NS
Total BMD Dist	650.40	79.40	739.37	56.48	14%	0.01
Area Prox	52.97	7.94	48.26	7.41	10%	NS
Area Regen	53.13	9.71	46.90	11.91	13%	NS
Area Dist	46.85	5.73	43.37	6.54	8%	NS

Example 3: Zoledronate in Distraction Osteogenesis (dose 0.1mg/kg)**Methods****Experimental Design**

Twenty-four eight-week-old male NZW rabbits underwent tibial lengthening. Similar rabbit models have been reported. After premedication with IM Ketamine 15 mg/kg and Xylazine 4mg/kg, anaesthesia was administered with Halothane 2%, and Oxygen 1 l/min. After preparation of the right lower extremity we performed an open mid-tibial drill hole osteotomy and applied an Orthofix M-100 fixator using four Orthofix 3 mm half pins (Orthofix, Bussolengo, Italy). The left lower extremity was left in tact. After a latency of 24 hours the tibia was lengthened 0.375mm every 12 hours for 14 days, producing a total of 10.5 mm of distraction. The fixator was then left in situ for 28 days to allow the regenerate to consolidate.

The animals were randomised such that eight animals were operated on and given saline-only infusions (controls), eight animals were given 0.1 mg/kg zoledronate over 20 minutes at the time of surgery (single dose zoledronate), and a further eight animals were given a second dose of zoledronate 0.1 mg/kg on day 14 (re-dosed zoledronate).

Buprenorphine 0.05 mg/kg was administered at the end of surgery and again 12 hours post operatively to all animals. The animals were supplied

with rabbit pellet and water ad libitum. At 42 days the rabbits were sacrificed with IV Lethobarb 150mg/kg.

Radiographic and Bone Mineral Density Analysis

Bone mineral content (BMC) and density (BMD) measurements were made at two, four and six weeks using a total body dual energy x-ray densitometer (LUNAR DPX, Radiation Corps, Madison, Wisconsin). DXA scans were performed with the tibia oriented in a jig in the antero-posterior (AP) projection, using software specifically designed for measuring small animals (LUNAR DPX, Small Animal Software. 1.0c LUNAR, Radiation Corps, Madison, Wisconsin). The "HiRes <0.5kg Slow" scan mode was used ("Fine" collimation, sample size of 0.6 x 1.2 mm. and sample interval of 1/16 seconds).

Regional BMC and BMD measurements were obtained by placing "regions of interest" (ROI's) 9.6 mm high on the scan images. For each lengthened tibia, one ROI was positioned in the regenerate, one proximal to it and one distal to it. In the non-operated tibia, two ROI's were placed so that they matched the distal and proximal ROI of the lengthened tibia (ie the same distance from the bone ends). A total of three measurements are thus generated for each lengthened tibia and two measurements for each non-operated tibia. BMC values were expressed in grams (g) and BMD values expressed as g/cm² and group data reported as mean, standard deviation and 95% confidence intervals.

After culling, both hind limbs were disarticulated through the knee and the soft tissues left intact. The limbs were oriented in standard AP and lateral projections and plain radiographs taken with a Siemens Multix H/UPH configuration using digital luminescent cassettes with a 50 kV and 4 mA exposure with a tube to film distance of 1.1 meters. A calibrated marker on the film allowed the image to be re-scaled appropriately for measurements of length in millimetres (mm).

To expand the analysis at six weeks the disarticulated bones were then stripped of all soft tissues and analysed using a Stratec XCT-960A pQCT scanner and analysis software (Stratec Medizintechnik GmbH, Pforzheim, Germany). Two millimetre slices were obtained, 15 slices in the right (lengthened) tibiae and 10 in the non-operated tibiae. Five slices were thus obtained in the regenerate, proximal and distal bone, and corresponding areas to the proximal and distal bone in the non-operated limb. The software

allowed analysis and generation of data on bone mineral density as g/cm³. bone mineral content (g) and cross sectional area (mm²). Data was also generated for mechanical analysis, namely moment of inertia (mm⁴), and maximum y co-ordinate (vertical distance from the neutral bending plane in mm).

Results

Exclusions

One rabbit in the single dose zoledronate group died suddenly of a gastrointestinal illness 9 days after surgery. One rabbit in the re-dosed group had failure of distraction and premature consolidation and was excluded. This left 8 rabbits in the control group and seven rabbits in each of the zoledronate groups.

Bone Mineral Content (BMC)

The BMC as measured by DXA was similar at two weeks in all groups (Fig. 8). There was a rapid increase in mineralisation of all three regions of the operated limb between week two and week four in the zoledronate treated animals. This was significantly different for treated groups over controls in all regions except for single dose animals in the distal segment (t test $p < 0.01$). There was a fall off in BMC between weeks four and six in all regions. This was most marked in control animals, much reduced in the single dose group and minimal in the double dose group, such that both treated groups had significantly increased BMC at six weeks over controls. The difference between single dose and redosed animals for BMC was significant at six weeks in the proximal and distal segments, but not in the regenerate ($p < 0.01$).

The velocity of bone mineral accrual in the regenerate was significantly higher between weeks 2 and 4 in the treated animals (Fig. 9, $p < 0.01$). Between weeks 4 and 6, when all groups shed some bone mineral, this was least so in the redosed zoledronate group ($p < 0.05$ v control, NS v single dose).

At six weeks the BMC as measured by QCT was increased significantly in all regions in the zoledronate treated animals ($p < 0.01$, ANOVA) (Fig. 10). The effect was enhanced in the double dose group in a dose-related fashion. Post-hoc t-tests revealed that the differences between single dose versus control and double dose versus single dose were both significant ($p < 0.05$). There was no significant change in the BMC in the non-operated tibiae.

Bone Mineral Density

The control group BMD in the regenerate as measured by DXA increased between weeks 2 and 4 but dropped off again to the 2-week value (Fig. 11). The BMD dropped off progressively in the proximal and distal regions, the expected effect of stress shielding (Fig. 11). In contradistinction, the BMD of the regenerate in the zoledronate treated animals increased more rapidly, and was largely maintained. The zoledronate served to protect the proximal and distal regions from the effects of stress shielding such that the BMD was maintained above two-week levels at six weeks. Both zoledronate treated groups had areal BMD values significantly different from controls at both 4 and 6 weeks by DXA, but the single dosed and redosed groups were never significantly different from each other for areal BMD.

At six weeks the volumetric BMD as measured by QCT was increased significantly in all regions in the zoledronate treated animals ($p < 0.01$, ANOVA) (Fig. 12). Post-hoc t-tests revealed that the differences between single dose versus control ($p < 0.01$), but no difference between re-dosed versus single dose ($p > 0.05$). There was no significant change in the BMC in the non-operated tibiae. The zoledronate treated animals maintained a BMD in all regions similar to that of the non-operated control tibiae whereas the control distracted tibiae showed a significant amount of osteoporosis in all regions.

Length Measurements at six weeks

There was a dose related difference in the lengths of the non-operated tibiae of the rabbits, such that the mean tibial length of the single zoledronate group was reduced by 3% over controls and the re-dosed group reduced by 7% (ANOVA $p < 0.01$ Table III). The re-dosed zoledronate group had significantly shorter operated right tibiae as well, but the regenerate lengths were not different between the groups. These data suggest a small but definite dose-related negative effect of zoledronate in longitudinal growth at the physis.

Cross-sectional Area Measurements at six weeks

There was a significant dose-dependant increase in cross sectional area in all regions in zoledronate treated animals as measured by QCT ($p < 0.01$, ANOVA). There was no effect at all on the cross sectional area of the non-operated tibiae (Fig. 13). The most marked effect was seen in the regenerate, with increases of 56% in the single dose group and 105% in the double dose

group, but considerable increases in cross sectional area of the adjacent regions was also seen, ranging from 29% to 72%. The median QCT scan for each group in terms of cross sectional area is shown in Figure 14

There were even larger increases in moment of inertia, as this is proportional to r^4 (Fig.14). The moment of inertia for the regenerate was thus increased by 111% in the single dose group and by 213% in the double dose group ($p=0.02$ ANOVA). The difference between single dose zoledronate and controls was significant by post-hoc unpaired t test ($p=0.02$). The further rise in moment in the repeat dose group did not reach significance, as the variability was high ($p=0.3$). Increases in moment of inertia in surrounding regions ranged from 57% to 180%.

Further study to examine the mechanical properties of the regenerate after administration of Zoledronate is required.

Discussion

Although given as a simple IV infusion, the significantly beneficial effects of zoledronate administration documented in this study were target organ specific (Figs 10, 12, 13, 14). A massive increase in both the amount of bone formed and its mineralisation, not only in the regenerate but also in adjacent regions was produced. Meanwhile there was little or no effect on the non-operated tibia. Several possible hypotheses may explain this. Although the pathway or even the cell line most directly involved have yet to be defined, zoledronate seems to produce an inability of the bone to sense its mechanical environment. Unlike control tibiae, in which the BMD progressively dropped, bone mineral was not shed in the bone surrounding the osteotomy and distraction. Meanwhile new bone formed in a more vigorous fashion than in controls, even though the bone was rigidly held in the fixator.

Another possibility is that osteoclastic inhibition delays remodelling until more than the usual amount of callus is formed. There is also the possibility that the bisphosphonates are acting directly on osteoblasts, perhaps through basic fibroblast growth factor (bFGF). Further study to try and elucidate exactly which growth factors have been stimulated or inhibited by bisphosphonate administration is required.

Of importance is the observation that the BMD was returned to the value of the control non-operated limb and the increases in BMC were largely due to increased amount of new bone of normal density. If the density to

supra-normal levels had simply been increased with no increased amount of bone formed, then the bone would be osteopetrotic. i.e. brittle and with no improvement in strength.

A single IV dose at time the time of surgery lends itself well to the clinical situation when managing skeletal trauma. Zoledronate has a well-documented safety profile in patients with cancer receiving multiple doses (Major P, Lortholary, Hon J *et al.* "Zoledronic acid is superior to pamidronate in the treatment of tumour-induced hypercalcaemia: a pooled analysis." Proc ASCO New Orleans, May 2000 19:209 (Abstract 814).. A single perioperative dose in a well-hydrated trauma patient should be well tolerated, if there is concern about hydration the treatment could be deferred until it was adequate. This would reduce the theoretical possibility of nephrotoxicity or nephrocalcinosis.

In elective situations the administration of IV zoledronate as a 5-20 minute infusion perioperatively should be easily and safely achieved. Further study is required.

If the treating physician considers the response to a single perioperative dose sub-optimal, or the treatment course is unusually prolonged, this study strongly suggests that a further dose will confer additional benefit. However as a single dose provides over 50% increase in new bone formation in this model, a further dose may not be routinely necessary. Likewise in the paediatric population, appropriate consideration must be given to the negative effects on longitudinal growth related to bisphosphonate administration. This study showed a dose related negative effect on longitudinal growth, although this was only 3% in single dose and 7% in re-dosed animals, it suggests that prolonged administration of zoledronate in growing children may be ill-advised.

The increase in cross sectional area is an extremely significant benefit. Regenerate failure has been documented to be largely in bending and fracture failure in long bones occurs in either bending or torsion. In both bending and torsion the moment of inertia is proportional to r^4 , or the square of the cross sectional area. The 56% increase in cross sectional area of regenerate thus translates to 111% increase in moment of inertia. The 105% increase in the re-dosed group equates to a 213% increase in moment of inertia. The regenerate strength index was increased also in proportion to the cross sectional area (Table IV).

The effects seen in this experiment are consistent with the above findings relating to pamidronate administration.

As the present model follows the animals for only six weeks, no conclusion regarding remodelling of the new bone formed can be reached. It is intuitive that the cross sectional area will reduce as the bone remodels. Producing such a large amount of callus may allow removal of the fixator before remodelling has occurred. This strategy would allow remodelling to occur in an environment exposed to physiological loading as the effects of the bisphosphonate wore off over time, rather than remodelling in the stress shielded environment of the fixator. Further studies to look at the behaviour of the bone after fixator removal are required.

TABLE III

Tibial and Regenerate Lengths for Control, Zoledronate and Re-dosed Zoledronate Group

		Control	Zoledronate 1	Zoledronate 2
Number		8	7	7
Left Tibia	Mean	98.00	95.14*	91.14*
	SD	1.41	2.48	2.79
Right Tibia	Mean	107.75	107.43	101.57*
	SD	2.12	4.08	3.21
Regenerate	Mean	10.38	11.29	10.57
	SD	1.30	1.50	1.90

* Denotes significantly different by ANOVA and post-hoc unpaired t-test

TABLE IV

Regenerate Strength Index for Control, Zoledronate and Re-dosed Zoledronate Group

	Control	Zoledronate 1	Zoledronate 2
RSI	2.09	3.26	4.49
% above control		56%	114%

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

CLAIMS:

1. A drug selected from the group consisting of at least one bisphosphonate when used for promoting new bone formation at a fracture site.
- 5 2. A drug selected from the group consisting of at least one bisphosphonate when used for treating a fractured bone.
3. The drug of claim 1 or claim 2 wherein the bisphosphonate is Zoledronate.
4. The drug of claim 1 or claim 2 wherein the drug is a combination of
- 10 two or more bisphosphonates.
5. The drug Zoledronate when used for promoting new bone formation.
6. The drug of claim 5 when used for promoting new bone formation between a bone and a prosthesis, bone fixation device or any other bone or dental implant.
- 15 7. The drug of any one of the preceding claims when administered to an individual as a single dose.
8. The drug of any one of the preceding claims when administered to an individual perioperatively.
9. Use of a drug selected from the group consisting of at least one
- 20 bisphosphonate for the manufacture of a medicament for promoting new bone formation at a fracture site.
10. Use of a drug selected from the group consisting of at least one bisphosphonate for the manufacture of a medicament for treating a fractured bone.
- 25 11. Use of the drug of claim 9 or claim 10 wherein the drug is Zoledronate.
12. Use of the drug of claim 9 or claim 10 wherein the drug is a combination of two or more bisphosphonates.
13. Use of the drug Zoledronate for the manufacture of a medicament for promoting new bone formation.
- 30 14. A method for treating a fractured bone, the method including administering to a subject with a fractured bone a therapeutically effective amount of a drug selected from the group consisting of at least one bisphosphonate.
15. The method of claim 14 wherein the drug is administered to the
- 35 subject as a single dose.
16. The method of claim 15 wherein the single dose of drug is

administered at an early stage of treatment of the fractured bone.

17. The method of claim 14 wherein the mode of administration is as a perioperative intravenous infusion.

18. The method of claim 14 wherein the mode of administration is oral.

5 19. The method of claim 14 wherein the mode of administration is transdermal.

20. A method of treating a fractured bone, the method including the steps of:

10 (a) administering to a subject with a fractured bone a therapeutically effective amount of a drug selected from the group consisting of at least one bisphosphonate; and

(b) providing a vibratory stimulus to the fractured bone.

21. The method of claim 20 wherein the vibratory stimulus is provided by ultrasound stimulation or vibration stimulation.

15 22. The method of claim 20 or claim 21 wherein the vibratory stimulus includes periodically providing a vibratory stimulus at the resonant frequency of the bone.

23. The method of claim 22 wherein the resonant frequency is calculated as a function of the bone's vibratory response to the vibratory stimulus.

20 24. The method of any one of claims 20 to 23 wherein the vibratory stimulus is provided at a late stage in the treatment of the fractured bone.

25 25. The method of any one of claims 20 to 23 wherein the step of providing a vibratory stimulus is concurrent with the step of administering a therapeutically effective amount of the drug.

26. The method of claim 25 wherein the vibratory stimulus is provided and the therapeutically effective amount of the drug is administered at an early stage in the treatment of a fractured bone.

30 27. A drug selected from the group consisting of at least one bisphosphonate when used for promoting new bone formation at a fracture site in an individual suffering from delayed union of a fracture.

28. A method for promoting new bone formation at a fracture site in a subject suffering from delayed union of a fracture, the method including administering to the subject a therapeutically effective amount of a drug selected from the group consisting of at least one bisphosphonate.

35 29. The method of claim 28 wherein the at least one bisphosphonate is administered parenterally as a single dose at or near the time of surgery.

30. The method of claim 29 wherein a further parenteral dose of the at least one bisphosphonate is administered about four to six weeks after the initial dose.

31. The method of claim 29 wherein further oral doses of the at least one bisphosphonate are administered in a daily or second daily regimen commencing about four to six weeks after the initial dose for a period of about two months or until sufficient new bone has been formed.

32. A method of promoting new bone formation in a subject, the method including the steps of surgically performing the procedure of distraction osteogenesis and administering to the subject a drug selected from the group consisting of at least one bisphosphonate.

33. The method of claim 32 wherein the at least one bisphosphonate is administered parenterally as a single dose at or near the time of surgery.

34. The method of claim 33 wherein a further parenteral dose of the at least one bisphosphonate is administered either at the end of the distraction period or up to three months after the initial dose.

35. The method of claim 33 wherein further oral doses of the at least one bisphosphonate are administered in a daily, second daily or weekly regimen.

36. The method of claim 35 wherein the regimen commences about one to three months after the initial parenteral dose for a period of about two months.


(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
1 March 2001 (01.03.2001)

PCT

(10) International Publication Number
WO 01/13922 A1

- (51) International Patent Classification: A61K 31/663, A61P 19/00 (74) Agent: F B RICE & CO: 605 Darling Street, Balmain, NSW 2041 (AU).
- (21) International Application Number: PCT/AU00/00982 (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 17 August 2000 (17.08.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: PQ 2325 19 August 1999 (19.08.1999) AU (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (for all designated States except US): THE ROYAL ALEXANDRA HOSPITAL FOR CHILDREN [AU/AU]; Cnr Hawkesbury Road & Hainsworth Street, Westmead, NSW 2145 (AU).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): LITTLE, David, G. [AU/AU]; Suite 3, Children's Hospital Medical Centre, Hainsworth Street, Westmead, NSW 2145 (AU).
- (54) Title: DRUG FOR TREATING FRACTURES
- Published:**
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


Control



(57) Abstract: A drug selected from a group consisting of bisphosphonates for promoting bone growth and for the treatment of a fracture.


1/20

Figure 1




2/20

Figure 2



3/20


Figure 3



4/20

Figure 4

Control v. Pamidronate



5/20

Figure 5

Pamidronate

Control


Regenerate:
Low Power

Regenerate:
High Power

Adjacent
Bone


6/20

Figure 6




7/20

Figure 7




8/20

Figure 8A




9/20

Figure 8B




10/20

Figure 8C




11/20

Figure 9




12/20

Figure 10




13/20

Figure 11A



14/20

Figure 11B



15/20

Figure 11C






Figure 12




17/20

Figure 13




18/20

Figure 14



19/20

Figure 15



20/20




FIG. 16

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF
ATTORNEY

(Includes Reference to PCT International Applications)

ATTORNEY'S DOCKET
NUMBER **RICE-006**

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

DRUG FOR TREATING FRACTURES

the specification of which (check only one item below):

☐ is attached hereto.

☐ was filed as United States application

Serial No.

on ,

and was amended

on _____ (if applicable).

☒ was filed as PCT international application

Number PCT/AU00/00982

on 17 Aug 2000,

and was amended under PCT Article 19

on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. 119:

COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 USC 119
Australia	PQ2325	19 Aug 1999	<input checked="" type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO
			<input type="checkbox"/> YES <input type="checkbox"/> NO

Combined Declaration For Patent Application and Power of Attorney (Continued)
(Includes Reference to PCT International Applications)

ATTORNEY'S DOCKET NUMBER
RICE-006

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120:

U.S. APPLICATIONS		STATUS (Check one)		
U.S. APPLICATION NUMBER	U.S. FILING DATE	PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (List name and registration number)

(11) Karl Bozicevic, Reg. No. 28,807
Bret E. Field, Reg. No. 37,820
Paula A. Bordon, Reg. No. 42,344
Alan W. Cannon, Reg. No. 34,977
Robert Hall, Reg. No. 39,209
David Phinney, Reg. No. 48,364

Carol L. Francis, Reg. No. 36,513
Pamela J. Sherwood, Reg. No. 36,677
Frank Becking, Reg. No. 42,309
Carol M. LaSalle, Reg. No. 39,740
Kathleen Hall, Reg. No. 44,143

Send Correspondence to:
BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

Direct Telephone Calls to:
(name and telephone number)
Name: Alan W. Cannon
Registration No. 28,807
Telephone: (650) 327-3400

201	FULL NAME OF INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
		<u>1-00 LITTLE</u>	<u>DAVID</u>	<u>GRAHAM</u>
	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
		<u>12 GLENVIEW AVE</u> <u>WEST PENNAUT</u> <u>HILLS NSW</u>	<u>AUSTRALIA</u>	<u>AUSTRALIA AUK</u>
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
		<u>As ABOVE</u>		

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.


SIGNATURE OF INVENTOR 201

DATE

WFO/M/IN/COM/TEC/WF 5/88

D-Little
4/4/02

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ *Scanned copy is best available.*

Parts of drawings
are dark.